Table 1.

Application of aptamer and chemotherapeutics combination strategies in the therapy of pancreatic cancer

S.No.	Aptamer	Drug	Targeting ligand	In vivo model	Route of administration	Cell line	Result	Ref.
1.	Wnt5a and FZD7	Gemcitabine	ABCG2	–	–	Capan-2	Wnt5a-induced resistance of gemcitabine in pancreatic tumour cells.	[98]
2.	APTA-12	Gemcitabine	Nucleolin	Mouse	Intravenous	Capan-1	Considerably increased targeting affinity and suppression of cancer cell growth.	[96]
3.	P12FR2	2′-fluoropyrimidine	PAUF	Mouse	Intraperitoneal	CFPAC-1	Inhibit metastasis and cell proliferation	[99]
4.	E07	Gemcitabine	EGFR	–	–	MiaPaCa-2 and HPAF-2	Targeted therapy increases effectiveness and reduce side effects.	[100]
5.	AS1411	AuNS	Nucleolin	–	–	PANC-1	Increase cell death and caspase activity in tumour cells.	[101]
6.	AP1153	CPSNPs	CCKBR	Mouse	Intraperitoneal	PANC-1	Enhanced delivery and absorption to pancreatic tumour cells.	[102]
7.	Waz and E07	MMAE and MMAF	EGFR, TfR	–	–	Panc-1, MIA PaCa-2, and BxPC3	Delivery of hazardous payloads specifically to pancreatic tumour cells.	[103]
8.	Ap52	Doxorubicin	MAGE-A3	Mouse	Intravenous, In situ	AsPC-1	Provide targeted drug delivery and combined modulation of cell immunity for cancer treatment.	[104]
9.	NF-κB	Doxorubicin	TfR	–	–	MIA PaCa-2	Improving the Dox-mediated apoptotic impact in the pancreatic cancer cells.	[105]
10.	P19	Gemcitabine, 5-FU and MMAE	–	–	–	AsPC-1	Significantly reduced cell growth and produced mitotic G2/M phase arrest.	[106]